Atypical chronic myeloid leukemia, BCR-ABL1 negative
MONDO:0004653A myelodysplastic/myeloproliferative neoplasm characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia. The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene. (WHO, 2001)
Also known as: aCML, atypical CML, atypical chronic myeloid leukaemia, atypical chronic myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 Negative, subacute granulocytic leukaemia, subacute granulocytic leukemia, subacute myelogenous leukaemia
3096 clinical trials for this condition and its sub-types, 17 tagged with Atypical chronic myeloid leukemia, BCR-ABL1 negative itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for rare blood cancers: fedratinib shows promise in early trial
Disease control CompletedThis study tested a drug called fedratinib in 25 adults with rare blood cancers (MDS/MPN and CNL). The goal was to see if the drug could shrink the spleen and improve blood counts. While not a cure, the treatment aims to control the disease and reduce symptoms.
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Drug cocktail shows promise against rare bone marrow cancers
Disease control CompletedThis study tested a combination of two drugs, ruxolitinib and azacytidine, in 121 people with myelofibrosis or related blood cancers. The goal was to see if the combo could shrink tumors or improve blood counts. While the treatment aims to control the disease, it is not a cure, a…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC